Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Accumulated Expenses (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Accumulated Expenses data on record, last reported at $21.8 million in Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 43.89% year-over-year to $21.8 million; the TTM value through Dec 2025 reached $21.8 million, up 43.89%, while the annual FY2025 figure was $21.8 million, 43.89% up from the prior year.
  • Accumulated Expenses reached $21.8 million in Q4 2025 per TGTX's latest filing, up from $15.0 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $21.8 million in Q4 2025 and bottomed at $1.6 million in Q1 2022.
  • Average Accumulated Expenses over 5 years is $8.5 million, with a median of $8.4 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 158.55% in 2021, then tumbled 66.57% in 2022.
  • A 5-year view of Accumulated Expenses shows it stood at $10.2 million in 2021, then decreased by 17.06% to $8.4 million in 2022, then soared by 44.35% to $12.2 million in 2023, then grew by 24.75% to $15.2 million in 2024, then skyrocketed by 43.89% to $21.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $21.8 million in Q4 2025, $15.0 million in Q3 2025, and $10.6 million in Q2 2025.